Topiramate, commonly known by its brand name Topamax, is a medication prescribed for epilepsy, migraine prevention, and sometimes off-label for other conditions. While effective for many people with neuropsychiatric conditions, topiramate is reported to have cognitive side effects in some patients.
Understanding what to expect from this medication, both common and serious effects, helps you make informed decisions about your treatment and know when to seek help.
Key Takeaways
Cognitive side effects are distinctive: Topiramate commonly causes word-finding difficulties, mental slowing, and concentration problems, affecting up to 10% of patients. These "brain fog" symptoms are dose-related and often improve with lower dosing or discontinuation.
Risk for kidney stones increases significantly: Studies show that long-term topiramate use is associated with kidney stones due to the medication causing metabolic acidosis and reducing urinary citrate levels.
Birth defects are a serious concern: Topiramate is classified as a Pregnancy Category D medication due to increased risk of cleft lip and palate in infants exposed during the first trimester of pregnancy. Topiramate users planning pregnancy should discuss concerns with a healthcare provider, as abruptly stopping the medication could cause serious problems.
What is Topiramate and How Does it Work?
Topiramate (Topamax) is an antiepileptic drug (AED) that the FDA approved in 1996 for treating seizures and migraine prevention. It works through multiple mechanisms, including reducing sodium channel activation, enhancing GABA activity, and inhibiting neuronal excitatory pathways through selective action at the AMPA receptors.
It also inhibits calcium-channels, reducing neurotransmitter release. This broad mechanism of action makes it effective for various conditions but also contributes to its side effect profile.
The medication is prescribed for epilepsy (both alone and with other medications), migraine prophylaxis (prevention) in adults and adolescents aged 12 and older, and sometimes off-label for conditions like bipolar disorder, PTSD, and weight management.
Common Cognitive Side Effects
Topiramate's most distinctive side effects affect thinking and language. Word-finding difficulties, often described as having "words on the tip of your tongue", affect some users. These problems likely stem from a drug-induced underactivation of Broca’s area in the brain, a region associated with verbal fluency. The extent of effects may be influenced by dose and individual sensitivity.
Research suggests that discontinuing or reducing the medication improves verbal functions.
Mental slowing and attention problems are dose-related, typically appearing during the first months of treatment. Short-term and working memory can also be affected.
Physical Side Effects
Tingling sensations: Numbness or tingling in hands, feet, or face (paresthesia) is very common, occurring because topiramate affects nerve signaling. This typically appears early and may decrease over time. Research suggests topiramate-induced paresthesia may be dependent on dose and duration.
Weight loss: Unlike many medications, topiramate often causes weight loss through decreased appetite. While sometimes welcome, unintended weight loss can be concerning, especially in children.
Metabolic Acidosis
Topiramate inhibits carbonic anhydrase enzymes, which can cause metabolic acidosis, a condition where too much acid builds up in your body. This occurs because topiramate reduces bicarbonate reabsorption in the kidneys, leading to acid accumulation.
In a study involving over 10,000 veterans, clinically significant metabolic acidosis (<17 mEq/L serum bicarbonate concentration) only occurred in 1.1% of topiramate-treated patients. Moreover, the prevalence of topiramate-induced metabolic acidosis was not dose-dependent.
Symptoms of metabolic acidosis may include rapid breathing, fatigue, confusion, and lack of appetite. Regular blood tests to monitor bicarbonate levels are recommended for patients on long-term topiramate therapy.
Kidney Stones
Topiramate significantly increases the risk of developing kidney stones, particularly calcium phosphate stones.
A recent study published in the American Journal of Kidney Diseases found that 2-3% of users on combined treatment of topiramate and zonisamide (another anti-epileptic drug) will experience a symptomatic kidney stone event during the first three years of treatment.
Why does this happen? Topiramate causes systemic metabolic acidosis, markedly lowers urinary citrate excretion (citrate normally prevents stone formation), and increases urine pH. These changes create an environment conducive to calcium phosphate stone formation.
Signs of kidney stones include severe back or side pain, pain during urination, blood in urine, nausea, and fever. If you experience these symptoms, seek medical attention promptly.
Other Serious Side Effects
Visual problems: Acute ocular conditions such as acute myopia and secondary angle-closure glaucoma have been reported but are rare. Immediate care is essential if symptoms arise. Symptoms include sudden vision decrease, eye pain, or redness requiring immediate medical attention.
Decreased sweating: Particularly concerning in children, reduced sweating increases overheating risk, especially during hot weather or physical activity.
Mood changes: Antiepileptic medications, including topiramate, carry an FDA-mandated warning about increased risk of suicidal ideation and behavior. Any new or worsening mood symptoms should be promptly discussed with a provider.
Gastrointestinal effects: Nausea, abdominal pain, diarrhea, and altered taste perception (especially carbonated beverages tasting flat) are common but usually mild.
Fatigue: Drowsiness is common when starting or increasing doses. Taking medication at bedtime may minimize daytime effects.
Drug Interactions and Pregnancy Concerns
Topiramate interacts with oral contraceptives (reducing effectiveness at doses above 200 mg daily) and valproic acid (increasing hyperammonemia and hypothermia risks).
Women of childbearing age need effective contraception when taking the medication, as topiramate is Pregnancy Category D due to increased cleft lip/palate risk and small-for-gestational-age infants. Topiramate users planning pregnancy should discuss concerns with their healthcare provider.
When to Seek Immediate Medical Attention
Contact emergency services or your healthcare provider immediately if you experience:
Signs of kidney stones (severe back/side/abdominal pain, bloody urine, fever)
Sudden vision problems or eye pain
Signs of metabolic acidosis (rapid breathing, confusion, extreme fatigue)
Thoughts of self-harm or suicide
Severe allergic reactions (difficulty breathing, facial swelling, severe rash)
Signs of decreased sweating with fever, especially in children
Symptoms of high ammonia levels (confusion, vomiting, unusual tiredness)
Managing Side Effects and Higher Risk Groups
For cognitive effects: Starting with low doses (50-100 mg daily) and increasing slowly helps minimize problems. Discuss dose reduction if cognitive effects significantly impact your life.
For kidney stone prevention: Adequate hydration is recommended, and healthcare providers may consider potassium citrate supplementation or bicarbonate monitoring when appropriate
For metabolic acidosis: Regular blood tests catch problems early. A diet rich in fruits and vegetables helps maintain acid-base balance.
Higher risk groups: Children (especially for decreased sweating and cognitive effects), people with kidney disease, women of childbearing age, those with kidney stone history, and individuals with baseline cognitive issues all face elevated risks and require closer monitoring.
Stopping Safely
Never stop topiramate suddenly—this can trigger seizures or rebound symptoms even in people taking it for migraines. Your provider will create a gradual tapering schedule over several weeks.
Getting Mental Health Treatment
If you're taking topiramate for migraines, seizures, or mood disorders and experiencing troubling side effects that affect your quality of life, modern telehealth psychiatry can help. Platforms like Blossom Health connect you with board-certified psychiatrists through virtual appointments covered by in-network insurance.
A psychiatrist can evaluate whether topiramate remains the best choice for your situation, adjust dosing to minimize side effects, or recommend alternative treatments.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988. Never stop taking topiramate or make changes to your treatment plan without consulting your healthcare provider first, as abrupt discontinuation can cause seizures even in patients taking it for non-seizure conditions.
Sources
U.S. Food and Drug Administration. (2017). Topamax (topiramate) tablets and capsules prescribing information (Label No. 020505s057 & 020844s048). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf
Fariba KA, Saadabadi A. Topiramate. [Updated 2024 Jun 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554530/
Mula, M., Trimble, M. R., Thompson, P., & Sander, J. W. (2003). Topiramate and word-finding difficulties in patients with epilepsy. Neurology, 60(7), 1104–1107. https://doi.org/10.1212/01.wnl.0000056637.37509.c6
De Ciantis, A., Muti, M., Piccolini, C., et al. (2008). A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. Neurological Sciences, 29(Suppl 1), 141–143. https://link.springer.com/article/10.1007/s10072-008-0906-5
Thompson, P. J., Baxendale, S. A., Duncan, J. S., & Sander, J. W. (2000). Effects of topiramate on cognitive function. Journal of neurology, neurosurgery, and psychiatry, 69(5), 636–641. https://pmc.ncbi.nlm.nih.gov/articles/PMC1763392/
Marino, S. E., Pakhomov, S. V. S., Han, S., Anderson, K. L., et al. (2012). The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. Epilepsy & Behavior, 24(3), 365–372. https://www.sciencedirect.com/science/article/abs/pii/S1525505012003289
Lee, H. W., Jung, D. K., Suh, C. K., Kwon, S. H., & Park, S. P. (2006). Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy & behavior : E&B, 8(4), 736–741. https://pubmed.ncbi.nlm.nih.gov/16647301/
Burton, L. A., & Harden, C. (1997). Effect of topiramate on attention. Epilepsy Research, 27(1), 29–32. https://www.sciencedirect.com/science/article/pii/S0920121196010157
Mula M. (2012). Topiramate and cognitive impairment: evidence and clinical implications. Therapeutic advances in drug safety, 3(6), 279–289. https://pmc.ncbi.nlm.nih.gov/articles/PMC4110841/
Sedighi, B., Shafiei, K., & Azizpour, I. (2016). Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. Neurological Sciences, 37(4), 585–589. https://link.springer.com/article/10.1007/s10072-015-2458-9
Naps, M. S., Leong, S. H., Hartwell, E. E., Rentsch, C. T., & Kranzler, H. R. (2023). Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans. Alcohol: Clinical and Experimental Research, 47(3), 438–447. https://doi.org/10.1111/acer.15011
Fichadiya, H. A., Lieske, J. C. (2025). Do topiramate and zonisamide cause kidney stones? American Journal of Kidney Diseases, 85(6), 674-675 https://doi.org/10.1053/j.ajkd.2025.00781-4
Welch, B. J., Graybeal, D., Moe, O. W., Maalouf, N. M., & Sakhaee, K. (2006). Biochemical and stone-risk profiles with topiramate treatment. American journal of kidney diseases : the official journal of the National Kidney Foundation, 48(4), 555–563. https://pubmed.ncbi.nlm.nih.gov/16997051/
Dell'Orto, V. G., Belotti, E. A., Goeggel-Simonetti, B., et al. (2014). Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. British journal of clinical pharmacology, 77(6), 958–964. https://pubmed.ncbi.nlm.nih.gov/24219102/
MotherToBaby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Topiramate (Topamax®) 2023 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582991/
U.S. Food and Drug Administration. (2011, March 4). FDA drug safety communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate). U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-risk-oral-clefts-children-born-mothers-taking-topamax-topiramate
